Similar articles for PMID: 28753811

Year	Number of Results
1994	1
1999	1
2000	1
2003	3
2004	1
2005	1
2007	1
2008	2
2009	7
2010	5
2011	17
2012	16
2013	21
2014	18
2015	24
2016	30
2017	37
2018	39
2019	41
2020	39
2021	33
2022	30
2023	18
2024	0

1

Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.

Yang DD, Mahal BA, Muralidhar V, Nezolosky MD, Vastola ME, Labe SA, Boldbaatar N, King MT, Martin NE, Orio PF 3rd, Beard CJ, Hoffman KE, Trinh QD, Spratt DE, Feng FY, Nguyen PL. Yang DD, et al. Eur Urol Focus. 2019 Jan;5(1):69-76. doi: 10.1016/j.euf.2017.05.011. Epub 2017 Jun 17. Eur Urol Focus. 2019. PMID: 28753811

2

Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance.

Yang DD, Mahal BA, Muralidhar V, Vastola ME, Boldbaatar N, Labe SA, Nezolosky MD, Orio PF 3rd, King MT, Martin NE, Mouw KW, Trinh QD, Nguyen PL. Yang DD, et al. Clin Genitourin Cancer. 2018 Jun;16(3):226-234. doi: 10.1016/j.clgc.2017.10.013. Epub 2017 Nov 9. Clin Genitourin Cancer. 2018. PMID: 29196209

3

Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.

Morlacco A, Cheville JC, Rangel LJ, Gearman DJ, Karnes RJ. Morlacco A, et al. Eur Urol. 2017 Sep;72(3):442-447. doi: 10.1016/j.eururo.2016.08.043. Epub 2016 Aug 27. Eur Urol. 2017. PMID: 27574819

4

Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer.

Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL. Dinh KT, et al. J Urol. 2015 Aug;194(2):343-9. doi: 10.1016/j.juro.2015.02.015. Epub 2015 Feb 11. J Urol. 2015. PMID: 25681290

5

Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.

Oh JJ, Hong SK, Lee JK, Lee BK, Lee S, Kwon OS, Byun SS, Lee SE. Oh JJ, et al. BJU Int. 2012 Dec;110(11 Pt B):E494-9. doi: 10.1111/j.1464-410X.2012.11182.x. Epub 2012 Apr 30. BJU Int. 2012. PMID: 22540236

6

Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility.

Schiffmann J, Wenzel P, Salomon G, Budäus L, Schlomm T, Minner S, Wittmer C, Kraft S, Krech T, Steurer S, Sauter G, Beyer B, Boehm K, Tilki D, Michl U, Huland H, Graefen M, Karakiewicz PI. Schiffmann J, et al. Urol Oncol. 2015 Jul;33(7):329.e13-9. doi: 10.1016/j.urolonc.2015.04.004. Epub 2015 May 7. Urol Oncol. 2015. PMID: 25960411

7

The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.

Corcoran NM, Casey RG, Hong MK, Pedersen J, Connolly S, Peters J, Harewood L, Gleave ME, Costello AJ, Hovens CM, Goldenberg SL. Corcoran NM, et al. BJU Int. 2012 Jul;110(1):36-42. doi: 10.1111/j.1464-410X.2011.10681.x. Epub 2011 Nov 15. BJU Int. 2012. PMID: 22085203

8

No detrimental effect of a positive family history on postoperative upgrading and upstaging in men with low risk and favourable intermediate-risk prostate cancer: implications for active surveillance.

Herkommer K, Maier N, Ankerst DP, Schiele S, Gschwend JE, Meissner VH. Herkommer K, et al. World J Urol. 2021 Jul;39(7):2499-2506. doi: 10.1007/s00345-020-03485-5. Epub 2020 Oct 13. World J Urol. 2021. PMID: 33048258 Free PMC article.

9

Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.

Caster JM, Falchook AD, Hendrix LH, Chen RC. Caster JM, et al. Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):244-51. doi: 10.1016/j.ijrobp.2015.01.051. Epub 2015 Apr 1. Int J Radiat Oncol Biol Phys. 2015. PMID: 25841621

10

Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.

Flood TA, Schieda N, Keefe DT, Breau RH, Morash C, Hogan K, Belanger EC, Mai KT, Robertson SJ. Flood TA, et al. Virchows Arch. 2016 Sep;469(3):313-9. doi: 10.1007/s00428-016-1981-2. Epub 2016 Jul 10. Virchows Arch. 2016. PMID: 27394432

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

299 results

Results by year